Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
2nd Edition: Combination and Innovative Therapies for Pancreatic Cancer
share announcement

2nd Edition: Combination and Innovative Therapies for Pancreatic Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: closed (10 April 2024) | Viewed by 2319

Special Issue Editor

Prof. Dr. Casper H. J. Van Eijck

E-Mail Website
Guest Editor
The Tumor Immuno-Pathology (TIP) Laboratory, Department of Surgery, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands
Interests: pancreatic cancer; surgery; neoadjuvant; immunotherapy; virotherapy; biomarkers; personalized medicine; chemo sensitivity
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This collection is the second edition of the previous Special Issue "Combination and Innovative Therapies for Pancreatic Cancer": https://www.mdpi.com/journal/cancers/special_issues/therapies_pancreatic.

The incidence of pancreatic cancer is still increasing worldwide; unfortunately, the prognosis remains dismal for most patients. Although some progression has been made recently with new chemotherapeutic regimens, especially for patients with resectable disease, new approaches to attack this aggressive disease are desperately needed. Among other new targeted therapies, immunotherapy, oncolytic virotherapy, and new locoregional therapies, applied either alone or in combination with existing therapies, are being investigated for use in metastatic, locally advanced, or resectable pancreatic cancer patients.

This Special Issue of Cancers will include basic, translational, and clinical studies focusing on new combination and innovative therapies in pancreatic cancer. Authors are also encouraged to present phase I/II studies with a scientific background. In addition, review articles related to innovative palliative therapy to improve the quality of life in patients with pancreatic cancer are also welcome. Our aim is to aid in the development of new strategies to treat this complex disease.

Prof. Dr. Casper H. J. Van Eijck
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pancreatic cancer
  • targeted therapy
  • immunotherapy
  • virotherapy
  • locoregional therapy
  • combination therapy

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

15 pages, 1885 KiB  
Article
Immunomodulatory Effects of Stereotactic Body Radiotherapy and Vaccination with Heat-Killed Mycobacterium Obuense (IMM-101) in Patients with Locally Advanced Pancreatic Cancer
by Freek R. van ‘t Land, Sai P. Lau, Willem de Koning, Larissa Klaase, Madelief Vink, Anneloes van Krimpen, Jasper Dumas, Disha Vadgama, Joost J. Nuyttens, Dana A. M. Mustafa, Ralph Stadhouders, Marcella Willemsen, Andrew P. Stubbs, Joachim G. Aerts and Casper H. J. van Eijck
Cancers 2022, 14(21), 5299; https://doi.org/10.3390/cancers14215299 - 27 Oct 2022
Cited by 1 | Viewed by 1939
Abstract
Background: Patients with locally advanced pancreatic cancer (LAPC) are treated with chemotherapy. In selected cases, stereotactic body radiotherapy (SBRT) can be added to the regimen. We hypothesized that adding an adjuvant containing a heat-killed mycobacterium (IMM-101) to SBRT may lead to beneficial immuno-modulatory [...] Read more.
Background: Patients with locally advanced pancreatic cancer (LAPC) are treated with chemotherapy. In selected cases, stereotactic body radiotherapy (SBRT) can be added to the regimen. We hypothesized that adding an adjuvant containing a heat-killed mycobacterium (IMM-101) to SBRT may lead to beneficial immuno-modulatory effects, thereby improving survival. This study aims to investigate the safety of adding IMM-101 to SBRT and to investigate the immuno-modulatory effects of the combination treatment in the peripheral blood of LAPC patients. Methods: LAPC patients were treated with SBRT (40 Gy) and six intradermal vaccinations of one milligram IMM-101. The primary endpoint was an observed toxicity rate of grade 4 or higher. Targeted gene-expression profiling and multicolor flow cytometry were performed for longitudinal immune-monitoring of the peripheral blood. Results: Twenty patients received study treatment. No treatment-related adverse events of grade 4 or higher occurred. SBRT/IMM-101 treatment induced a transient decrease in different lymphocyte subsets and an increase in CD14+CD16−CD11b+HLA−DRlow myeloid-derived suppressor cells. Importantly, treatment significantly increased activated ICOS+, HLA-DR+ and Ki67+PD1+ T and NK cell frequencies. This was not accompanied by increased levels of most inhibitory markers, such as TIM-3 and LAG-3. Conclusions: Combination therapy with SBRT and a heat-killed mycobacterium vaccine was safe and had an immune-stimulatory effect. Full article
(This article belongs to the Special Issue 2nd Edition: Combination and Innovative Therapies for Pancreatic Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop